MedPath

Digital Memory Album on Psychosocial Wellbeing among People with Dementia Living in Community – A Single Blind Randomised Controlled Trial

Not Applicable
Completed
Conditions
Dementia
Cognitive Impairment
Neurological - Dementias
Registration Number
ACTRN12622000269730
Lead Sponsor
niversity Kebangsaan Malaysia
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
30
Inclusion Criteria

•Participants aged 60 years old and above, ambulatory and community dwelling with a diagnosis of dementia according to DSM-5 by a psychogeriatrician.
•The rating of the Clinical Dementia Rating (Hughes et al., 1982) should be stage 1 (mild) or stage 2 (moderate).
•Participants should have sufficient abilities to speak, write and read in Malay language.
•Participants and relatives (caregivers) were willing to participate and consent for the study.
•Participants must have a relative, close friend, or care staff member who is willing to participate in tasks which require an informant perspective and give necessary additional life history of participant.

Exclusion Criteria

Participants were excluded from the study if they had a history of psychosis based on medical record, presence of psychiatric diagnosis (based on DSM-5) other than dementia (major neurocognitive disorders), severe physical condition or uncorrected sensory problem e.g. vision or hearing and severe dementia.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Quality of Life-Alzheimer’s Disease (QOL-AD) (Logsdon, Gibbons, McCurry, & Teri, 2002)[Baseline, at 8 weeks (at the end of intervention, primary endpoint) and at 14 weeks (follow-up from baseline)];Addenbrooke’s Cognitive Examination III (ACE-III) (Hsieh, Schubert, Hoon, Mioshi, & Hodges, 2013)[Baseline, at 8 weeks (at the end of intervention, primary endpoint) and at 14 weeks (follow-up from baseline)];Geriatric Depression Scale-Short Form (GDS-15) (Yesavage & Sheikh, 1986)[Baseline, at 8 weeks (at the end of intervention, primary endpoint) and at 14 weeks (follow-up from baseline)]
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath